As part of the Premio Brescia per la Ricerca Scientifica 2026, l'Università di Brescia presents a lecture by Prof. Alessandro Santin entitled “Precision medicine in gynecological oncology.”
Friday, February 13, 5:00 p.m.
Salone Apollo of the Rectorate, Piazza Mercato 15
Institutional greetings
Prof. Francesco Castelli - Rector of the Università di Brescia
Prof. Renata Mansini - Vice Rector for Research at the Università di Brescia
Prof. Sergio Pecorelli - Professor Emeritus of Gynecology and Obstetrics
BRESCIA AWARD FOR SCIENTIFIC RESEARCH 2026
Prof. Alessandro D. Santin was born in Italy and graduated with honors from the University of Brescia, where he also completed his postgraduate training in Obstetrics and Gynecology. He completed a fellowship in Gynecologic Oncology and Immunology at the University of California, Irvine, and an International Fellowship in Gynecologic Oncology at the University of Arkansas for Medical Sciences, Little Rock, Arkansas. Dr. Santin joined the medical and research staff of the Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale University as a Full Professor in July 2008.
Prof. Santin has more than 400 original publications in the scientific literature, including numerous review articles and book chapters on various topics, including ovarian, endometrial, and cervical cancer, as well as tumor immunology and immunotherapy, tumor genetics, and precision therapies for gynecologic cancers.
Throughout his career, he has received numerous research grants from federal agencies such as the National Cancer Institute, the National Institute of Health, and the Department of Defense, as well as from private foundations (Stand Up To Cancer, SU2C). Throughout his career, he has received numerous research grants from federal agencies such as the National Cancer Institute, the National Institutes of Health, and the Department of Defense, as well as from private foundations (Stand Up To Cancer, SU2C). Dr. Santin's translational and clinical studies led to the Food and Drug Administration (FDA) approval of Sacituzumab Govitecan (Trodelvy) in patients with breast cancer, the use of the combination of avutometinib and defactinib (AVMAPKI FAKZYNJA) in patients with low-grade ovarian cancer, as well as changes in the National Comprehensive Cancer Network (NCCN) guidelines for the treatment of patients with serous uterine cancer (the most biologically aggressive form) and patients with platinum-resistant ovarian cancer using trastuzumab and ixabepilone/bevacizumab, respectively. Prof. Santin's clinical interests include the use of immunotherapy in patients with ovarian, cervical, and endometrial cancer, therapeutic vaccines against human papillomavirus (HPV)-infected tumors, and the development of personalized treatment modalities, including monoclonal antibody therapies and antibody-drug conjugates (ADCs) against gynecological cancers resistant to traditional therapies.